Human Genome Rejects $2.6B Bid From GlaxoSmithKline (Update 1)
Updated with further information on GlaxoSmithKline's unsolicited bid for Human Genome
NEW YORK ( TheStreet) -- Human Genome Sciences (HGSI) received an unsolicited buyout proposal of $13 a share in cash, or about $2.6 billion, from GlaxoSmithKline (GSK) but rejected the offer saying the bid "does not reflect the value inherent" in the company.
The Glaxo bid represents an 81% premium to Human Genome's closing price Wednesday of $7.17.
Human Genome shares were up 104% to $14.67 in pre-market trading.Human Genome, in a press release Thursday, said its board has authorized the exploration of strategic alternatives, "including, but not limited to, a potential sale of the company." Glaxo has been invited to take part in the process. Human Genome and Glaxo are partners on the lupus treatment Benlysta, approved in March 2011. The commercial launch of Benlysta, however, has been slowed by lackluster interest from doctors and reimbursement hurdles; sales have fallen short of Wall Street expectations so far. Until today's Glaxo bid, Human Genome shares had lost 75% of their value since Benlysta's launch. Benlysta's poor sales made Human Genome a rich target for short sellers, who controlled 22% of the stock's float, according to Bloomberg. That's the 10th-highest short interest among biotech and drug stocks. Goldman Sachs and Credit Suisse have been hired as advisers to Human Genome. --Written by Adam Feuerstein in Boston with assistance from Joseph Woelfel in New York.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV